| Obesity

Xenical vs Foundayo

Side-by-side clinical, coverage, and cost comparison for obesity.

Deep comparison between: Xenical vs Foundayo with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsFoundayo has a higher rate of injection site reactions vs Xenical based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Foundayo but not Xenical, including UnitedHealthcare

Category

Xenical

Foundayo

At A Glance

RouteOral

FrequencyThree times daily

ClassGastrointestinal lipase inhibitor

RouteOral

FrequencyDaily

ClassGLP-1 receptor agonist

Indications

Obesity

Obesity

Dosing

Obesity One 120-mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal); distribute daily fat, carbohydrate, and protein over three main meals.

Obesity Start at 0.8 mg orally once daily; escalate to 2.5 mg, then 5.5 mg, then optionally to 9 mg, 14.5 mg, or 17.2 mg (maximum) once daily, increasing at intervals of at least 30 days based on tolerability; take with or without food; swallow tablets whole.

Contraindications

Pregnancy
Chronic malabsorption syndrome
Cholestasis
Known hypersensitivity to XENICAL or to any component of this product

Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
Known serious hypersensitivity to orforglipron or any excipient in FOUNDAYO

Drug Interactions

859View drug interactions

0View drug interactions

Adverse Reactions

Most common (>=5%) Oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, fecal incontinence

Postmarketing Hepatitis, hepatic failure, hypersensitivity reactions (pruritus, rash, urticaria, angioedema, bronchospasm, anaphylaxis), bullous eruption, leukocytoclastic vasculitis, acute oxalate nephropathy, pancreatitis, lower gastrointestinal bleeding

Most common (>=5%) Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, hair loss

Serious Thyroid C-cell tumors, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation

Postmarketing Hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure sometimes requiring hemodialysis

Pharmacology

Orlistat is a reversible inhibitor of gastrointestinal lipases that forms a covalent bond with the active serine residue site of gastric and pancreatic lipases, preventing hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, resulting in a caloric deficit that may have a positive effect on weight control.

Orforglipron is a small-molecule GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor, reducing appetite and caloric intake by activating GLP-1 receptors in brain regions that regulate appetite and food intake, and also delays gastric emptying.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Xenical